Bulk Inquiry
RKI 1447
- Soluble in DMSO
- MF: C16H14N4O2S
- MW: 326.37
Description
RKI 1447 is a potent inhibitor of Rho-associated ROCK kinases with reported IC50 values of 14.5 nM for ROCK1 and 6.2 nM for ROCK2. It is a type I inhibitor that binds the ATP site, including hinge-region and DFG motif interactions.
ROCK1/2 regulate actomyosin contractility, migration, invasion and tumor-associated cytoskeletal remodeling. RKI 1447 is relevant for anti-invasive oncology studies and Rho/ROCK pathway pharmacology.
Key Features
- Potent ROCK1 and ROCK2 inhibitor
- Type I ATP-site kinase inhibitor
- Targets hinge and DFG motif interactions
- Anti-invasive and antitumor activity reported in breast cancer models
Applications
- ROCK kinase assays
- Rho/ROCK signaling research
- Breast cancer invasion studies
- Cytoskeletal contractility and migration assays
More Information
| Parent CAS No. | 1342278-01-6 |
|---|---|
| Chemical Name | 1-(3-hydroxybenzyl)-3-(4-(pyridin-4-yl)thiazol-2-yl)urea |
| SMILES | N(CC1=CC=CC(O)=C1)C(NC1=NC(C2C=CN=CC=2)=CS1)=O |
| MFCD | N.A. |
| InChi | InChI=1S/C16H14N4O2S/c21-13-3-1-2-11(8-13)9-18-15(22)20-16-19-14(10-23-16)12-4-6-17-7-5-12/h1-8,10,21H,9H2,(H2,18,19,20,22) |
| InChiKey | GDVRVPIXWXOKQO-UHFFFAOYSA-N |
| CID | 60138149 |
| Short Description | ROCK inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1167 | GSK 269962A |
From $77.00 |
| 1535 | Thiazovivin |
From $99.00 |
| 1683 | Y 27632 dihydrochloride |
From $71.50 |
| 2166 | AT 13148 dihydrochloride |
From $77.00 |
| 2187 | AS 1892802 |
From $104.50 |
| 2331 | FRAX 486 |
From $99.00 |
| 2753 | CCG 232601 |
From $176.00 |
| 2780 | KD025 |
From $104.50 |
| 3092 | CCG-203971 |
From $66.00 |
| 3848 | Fasudil hydrochloride |
From $55.00 |
